Sadie Dobrozsi, MD, MS

Urban Health Today

Sadie Dobrozsi, MD, MS, medical director of genetic testing and oncology imaging for Evolent, dives into the biology behind why human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer is a challenging subtype to treat.

Unpacking Treatment Challenges in HER2+ Metastatic Breast Cancer

Breast Cancer Disparities

Lou Portero

Coca-Cola Faces Pressure to Return to Cane Sugar

Public Health

Hypertensive Disorders During Pregnancy Create Breastfeeding Barriers for American Women

Heart Disease in Women

Latest News

Sadie Dobrozsi, MD, MS, discusses the biology behind why HER2+ metastatic breast cancer is a challenging subtype to treat.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe